Abbott Laboratories (ABT) has initiated a medical device correction in the United States for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus continuous glucose monitoring systems after internal testing found that some sensors may deliver incorrect low glucose readings.
The company said it has identified and resolved the issue, which was linked to one of the production lines manufacturing the sensors. Abbott added that it continues to produce Libre 3 and Libre 3 Plus sensors to support replacements and new orders, and it does not expect significant supply disruptions.
The action covers about 3 million sensors in the U.S., roughly half of which are estimated to have expired or already been used. Globally, Abbott has received 736 reports of severe adverse events and seven potentially related deaths.
Abbott advised consumers to visit www.FreeStyleCheck.com to determine whether their sensor is potentially affected. Impacted sensors will be replaced at no cost, and detailed instructions for checking devices and requesting replacements are available on the site.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.